White Blood Cell News and Research

RSS

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.

20 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Vesicular stomatitis virus kills tumour, stimulates immune response against cancer: Research

Cancer Research UK scientists have used the immune system coupled with a virus found in horses and cattle, to hunt and purge cancer cells through the lymphatic system, a study reveals in Nature Medicine.Studying mice, the researchers found that the vesicular stomatitis virus (VSV), carried by a type of white blood cell called T cells acted as a 'cancer hunter', tracking down tumour cells in the lymph nodes, liver and spleen, and killed them, leaving normal healthy cells unharmed. At the same time, VSV also helped to trigger an immune response against the tumour, significantly improving the anti-cancer effect.

6 Aug 2010

New article published in Journal of Surgical Research highlights PACE technology

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced that an article titled "Microvascular Response to Shock Wave Application in Striated Skin Muscle" was recently published in the on-line edition of the Journal of Surgical Research.

4 Aug 2010

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

4 Aug 2010

New paradigm in TB research may lead to improved vaccination, treatment

Often causing no symptoms in carriers of the disease, worldwide tuberculosis (TB) infects eight to ten million people every year, kills two million, and it is highly contagious as it is spread through coughing and sneezing. "It's a global health disaster waiting to happen, even here in Canada, but this new paradigm in TB research may offer an immediate opportunity to improve vaccination and treatment initiatives," explains Dr. Maziar Divangahi of McGill University and of the Research Institute of the McGill University Health Centre.

30 Jul 2010

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Scientists at Washington University School of Medicine in St. Louis have found a way to significantly reduce atherosclerosis in mice that does not involve lowering cholesterol levels or eliminating other obesity-related problems.

26 Jul 2010

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

New research from The Methodist Hospital in Houston shows that sepsis is 10 times more common and more lethal than other more well-known surgical complications including heart attacks and blood clots. These results, published today in the Archives of General Surgery, show a greater need for sepsis awareness and early recognition during and after surgery.

21 Jul 2010

GCSF administration can reduce side effects of cancer neurobastoma in children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

21 Jul 2010

Two missing genes can develop aggressive form of leukaemia in mice: Research

A completely new mechanism that leads to the development of a certain type of leukaemia could eventually be targeted by new treatments, according to research published in Nature Immunology today (Sunday).

12 Jul 2010

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

AmpliMed Corporation, a cancer therapeutics company, today announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas.

12 Jul 2010

Importance of cell-cell communication in ischaemia

A team from the Bristol Heart Institute have investigated the importance of cell-cell communication in regulating the formation of new blood vessels following the restriction in blood supply to the heart or back leg in mice.

29 Jun 2010

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor Pharmaceutical Corp. announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

28 Jun 2010

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

A white blood cell that normally removes bacteria from the bloodstream helps Escherichia coli (E. coli) accumulate in the blood and enter the brain resulting in the deadly infection known as meningitis. Prasadarao V. Nemani, PhD, a scientist at The Saban Research Institute at Children Hospital Los Angeles plans to find out how this happens with a grant of $1.65 million from the National Institutes of Health - National Institute of Neurological Disorders and Strokes.

25 Jun 2010

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. One of the grants supports the first large, multi-center, randomized clinical trial to compare outcomes in heart surgery patients who receive transfusions of red blood cells that have been stored for shorter or longer amounts of time.

22 Jun 2010

FDA approves new indication for Tasigna in treatment of rare blood cancer

The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

18 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

Research findings could lead to less invasive treatments for ALL

A team of researchers from the Institute for Research in Immunology and Cancer of the Universit- de Montr-al have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. Published in the journal Genes and Development, the findings offer insight on the complex interaction between the genes and their contributions to leukemia, thereby providing the foundation for the design of targeted therapies.

17 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

White Blood Cell News and Research

Tasigna receives approval for chronic myeloid leukemia in Canada

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Vesicular stomatitis virus kills tumour, stimulates immune response against cancer: Research

New article published in Journal of Surgical Research highlights PACE technology

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

New paradigm in TB research may lead to improved vaccination, treatment

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

GCSF administration can reduce side effects of cancer neurobastoma in children

Two missing genes can develop aggressive form of leukaemia in mice: Research

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

Importance of cell-cell communication in ischaemia

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

FDA approves new indication for Tasigna in treatment of rare blood cancer

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

Research findings could lead to less invasive treatments for ALL

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

Immunology eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News